Literature DB >> 21568322

Discovery and characterization of small molecule inhibitors of the BET family bromodomains.

Chun-Wa Chung1, Herve Coste, Julia H White, Olivier Mirguet, Jonathan Wilde, Romain L Gosmini, Chris Delves, Sylvie M Magny, Robert Woodward, Stephen A Hughes, Eric V Boursier, Helen Flynn, Anne M Bouillot, Paul Bamborough, Jean-Marie G Brusq, Francoise J Gellibert, Emma J Jones, Alizon M Riou, Paul Homes, Sandrine L Martin, Iain J Uings, Jerome Toum, Catherine A Clement, Anne-Benedicte Boullay, Rachel L Grimley, Florence M Blandel, Rab K Prinjha, Kevin Lee, Jorge Kirilovsky, Edwige Nicodeme.   

Abstract

Epigenetic mechanisms of gene regulation have a profound role in normal development and disease processes. An integral part of this mechanism occurs through lysine acetylation of histone tails which are recognized by bromodomains. While the biological and structural characterization of many bromodomain containing proteins has advanced considerably, the therapeutic tractability of this protein family is only now becoming understood. This paper describes the discovery and molecular characterization of potent (nM) small molecule inhibitors that disrupt the function of the BET family of bromodomains (Brd2, Brd3, and Brd4). By using a combination of phenotypic screening, chemoproteomics, and biophysical studies, we have discovered that the protein-protein interactions between bromodomains and acetylated histones can be antagonized by selective small molecules that bind at the acetylated lysine recognition pocket. X-ray crystal structures of compounds bound into bromodomains of Brd2 and Brd4 elucidate the molecular interactions of binding and explain the precisely defined stereochemistry required for activity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21568322     DOI: 10.1021/jm200108t

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  104 in total

Review 1.  Epigenetic protein families: a new frontier for drug discovery.

Authors:  Cheryl H Arrowsmith; Chas Bountra; Paul V Fish; Kevin Lee; Matthieu Schapira
Journal:  Nat Rev Drug Discov       Date:  2012-04-13       Impact factor: 84.694

Review 2.  BET domain co-regulators in obesity, inflammation and cancer.

Authors:  Anna C Belkina; Gerald V Denis
Journal:  Nat Rev Cancer       Date:  2012-06-22       Impact factor: 60.716

Review 3.  Unravelling the genomic targets of small molecules using high-throughput sequencing.

Authors:  Raphaël Rodriguez; Kyle M Miller
Journal:  Nat Rev Genet       Date:  2014-10-14       Impact factor: 53.242

Review 4.  The bromodomain: from epigenome reader to druggable target.

Authors:  Roberto Sanchez; Jamel Meslamani; Ming-Ming Zhou
Journal:  Biochim Biophys Acta       Date:  2014-03-28

5.  RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.

Authors:  Sarah Picaud; Christopher Wells; Ildiko Felletar; Deborah Brotherton; Sarah Martin; Pavel Savitsky; Beatriz Diez-Dacal; Martin Philpott; Chas Bountra; Hannah Lingard; Oleg Fedorov; Susanne Müller; Paul E Brennan; Stefan Knapp; Panagis Filippakopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-18       Impact factor: 11.205

6.  BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.

Authors:  Mary A Morse; Karla K Balogh; Sarah A Brendle; Colin A Campbell; Mao X Chen; Rebecca C Furze; Isobel L Harada; Ian D Holyer; Umesh Kumar; Kevin Lee; Rab K Prinjha; Martin Rüdiger; Jonathan T Seal; Simon Taylor; Jason Witherington; Neil D Christensen
Journal:  Antiviral Res       Date:  2018-04-11       Impact factor: 5.970

7.  Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes.

Authors:  Janine M Lamonica; Wulan Deng; Stephan Kadauke; Amy E Campbell; Roland Gamsjaeger; Hongxin Wang; Yong Cheng; Andrew N Billin; Ross C Hardison; Joel P Mackay; Gerd A Blobel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-02       Impact factor: 11.205

Review 8.  Targeting bromodomains: epigenetic readers of lysine acetylation.

Authors:  Panagis Filippakopoulos; Stefan Knapp
Journal:  Nat Rev Drug Discov       Date:  2014-04-22       Impact factor: 84.694

9.  1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain.

Authors:  Emmanuel H Demont; Paul Bamborough; Chun-Wa Chung; Peter D Craggs; David Fallon; Laurie J Gordon; Paola Grandi; Clare I Hobbs; Jameed Hussain; Emma J Jones; Armelle Le Gall; Anne-Marie Michon; Darren J Mitchell; Rab K Prinjha; Andy D Roberts; Robert J Sheppard; Robert J Watson
Journal:  ACS Med Chem Lett       Date:  2014-09-10       Impact factor: 4.345

Review 10.  Tetrazoles via Multicomponent Reactions.

Authors:  Constantinos G Neochoritis; Ting Zhao; Alexander Dömling
Journal:  Chem Rev       Date:  2019-02-01       Impact factor: 60.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.